|
1
|
Sugimura H, Nichols FC, Yang P, et al:
Survival after recurrent nonsmall-cell lung cancer after complete
pulmonary resection. Ann Thorac Surg. 83:409–418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Théry C, Zitvogel L and Amigorena S:
Exosomes: composition, biogenesis and function. Nat Rev Immunol.
2:569–579. 2002.
|
|
3
|
Lamparski HG, Metha-Damani A, Yao JY, et
al: Production and characterization of clinical grade exosomes
derived from dendritic cells. J Immunol Methods. 270:211–226. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chaput N and Théry C: Exosomes: immune
properties and potential clinical implementations. Semin
Immunopathol. 33:419–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohshima K, Inoue K, Fujiwara A, et al:
Let-7 microRNA family is selectively secreted into the
extracellular environment via exosomes in a metastatic gastric
cancer cell line. PLoS One. 5:e132472010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang J, Zhang Y, Luo C, Xia Y, Chen H and
Wu X: Glycosyl-phosphatidylinositol-anchored interleukin-2
expressed on tumor-derived exosomes induces antitumor immune
response in vitro. Tumori. 96:452–459. 2010.
|
|
7
|
Zhang Y, Wu XH, Luo CL, Zhang JM, He BC
and Chen G: Interleukin-12-anchored exosomes increase cytotoxicity
of T lymphocytes by reversing the JAK/STAT pathway impaired by
tumor-derived exosomes. Int J Mol Med. 25:695–700. 2010.PubMed/NCBI
|
|
8
|
Dai S, Wan T, Wang B, et al: More
efficient induction of HLA-A*0201-restricted and carcinoembryonic
antigen (CEA)-specific CTL response by immunization with exosomes
prepared from heat-stressed CEA-positive tumor cells. Clin Cancer
Res. 11:7554–7563. 2005.
|
|
9
|
Xiu F, Cai Z, Yang Y, Wang X, Wang J and
Cao X: Surface anchorage of superantigen SEA promotes induction of
specific antitumor immune response by tumor-derived exosomes. J Mol
Med (Berl). 85:511–521. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Armitage RJ, Fanslow WC, Strockbine L, et
al: Molecular and biological characterization of a murine ligand
for CD40. Nature. 357:80–82. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melief CJ: Cancer immunotherapy by
dendritic cells. Immunity. 29:372–383. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dohnal AM, Luger R, Paul P, Fuchs D and
Felzmann T: CD40 ligation restores type 1 polarizing capacity in
TLR4-activated dendritic cells that have ceased interleukin-12
expression. J Cell Mol Med. 13:1741–1750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Elmetwali T, Searle PF, McNeish I, Young
LS and Palmer DH: CD40 ligand induced cytotoxicity in carcinoma
cells is enhanced by inhibition of metalloproteinase cleavage and
delivery via a conditionally-replicating adenovirus. Mol Cancer.
9:522010. View Article : Google Scholar
|
|
14
|
van Kooten C and Banchereau J: CD40-CD40
ligand. J Leukoc Biol. 67:2–17. 2000.
|
|
15
|
Van Nuffel AM, Corthals J, Neyns B,
Heirman C, Thielemans K and Bonehill A: Immunotherapy of cancer
with dendritic cells loaded with tumor antigens and activated
through mRNA electroporation. Methods Mol Biol. 629:405–452.
2010.PubMed/NCBI
|
|
16
|
Dai S, Zhou X, Wang B, et al: Enhanced
induction of dendritic cell maturation and HLA-A*0201-restricted
CEA-specific CD8(+) CTL response by exosomes derived from IL-18
gene-modified CEA-positive tumor cells. J Mol Med (Berl).
84:1067–1076. 2006.
|
|
17
|
Chen W, Wang J, Shao C, et al: Efficient
induction of antitumor T cell immunity by exosomes derived from
heat-shocked lymphoma cells. Eur J Immunol. 36:1598–1607. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miller MJ, Foy KC and Kaumaya PT: Cancer
immunotherapy: present status, future perspective, and a new
paradigm of peptide immunotherapeutics. Discov Med. 15:166–176.
2013.PubMed/NCBI
|
|
19
|
Escudier B, Dorval T, Chaput N, et al:
Vaccination of metastatic melanoma patients with autologous
dendritic cell (DC) derived-exosomes: results of thefirst phase I
clinical trial. J Transl Med. 3:102005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morse MA, Garst J, Osada T, et al: A phase
I study of dexosome immunotherapy in patients with advanced
non-small cell lung cancer. J Transl Med. 3:92005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei H, Wang H, Lu B, et al: Cancer
immunotherapy using in vitro genetically modified targeted
dendritic cells. Cancer Res. 68:3854–3862. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perrot I, Blanchard D, Freymond N, et al:
Dendritic cells infiltrating human non-small cell lung cancer are
blocked at immature stage. J Immunol. 178:2763–2769. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen T, Guo J, Yang M, Zhu X and Cao X:
Chemokine-containing exosomes are released from heat-stressed tumor
cells via lipid raft-dependent pathway and act as efficient tumor
vaccine. J Immunol. 186:2219–2228. 2011. View Article : Google Scholar : PubMed/NCBI
|
